Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer To Take Zinplava Rival Into Phase III For C Diff

Executive Summary

Pfizer will start a Phase III trial for its Clostridium difficile vaccine by the middle of the year, taking aim at the chinks in the armour of Merck & Co’s recently approved Zinplava, but it still trails its rival from Sanofi.

Advertisement

Related Content

Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development
Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity
Actelion Setback Ahead Of J&J Deal Closure
Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials
Merck & Co Expands C Diff Franchise With US Zinplava Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel